As an investor with the Health Fund at Earlybird Venture Capital, my role spans the full investment lifecycle from deal sourcing and due diligence to deal execution and portfolio support. I currently serve as Board Director of Hilo (Aktiia), Ariceum Therapeutics, and Noscendo, and as a board observer at Alesi Surgical and Shape Memory Medical.

My investment focus lies at the intersection of digital health, medical technologies, diagnostics, biopharma, and R&D platforms, sectors where cutting-edge science meets real-world clinical impact.

Prior to joining Earlybird in 2018, I spent over seven years conducting research across leading labs in Germany and Australia, and earned a PhD in Synthetic Biology from the Technical University of Munich.